55 -1 (29/2) 2020 — Igamberdiyeva R.Sh., Abdullayev Sh.S., — ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE

ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE

Igamberdiyeva R.Sh., Tashkent pediatric medical institute,

 Abdullayev Sh.S., Tashkent pediatric medical institute,

Yerina M.U., St.Petersburg State Pediatric Medical University.

Resume,

In patients with chronic kidney disease (CKD), develop bleeding and thrombotic tendencies, so the indication of anticoagulation therapy at the onset of atrial fibrillation (AF) is complex. AF is the most common chronic cardiac arrhythmia, and thromboembolism and ischemic stroke in particular are major complications.

Keywords: chronic kidney disease, atrial fibrillation, new oral anticoagulants.

First page

201

Last page

204

For citation: Igamberdiyeva R.Sh. Abdullayev Sh.S, Yerina M.U., Atrial fibrillation and chronic kidney disease//New Day in Medicine 1(29)2020 201-204 https://cutt.ly/9vCo33h

List of References

  1. Olesen J.B. et al, Stroke and bleeding in atrial fibrillation with chronic kidney desease. N Engl J Med. 2012; 367(7): 625-35.
  2. Kirchhof P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organization (ESO). Eur Heart J. 2016.
  3. Hijazi Z. et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Circulation. 2014; 129(9): 961-70.
  4. Fox K.A. et al. Prevention of stroke Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J.2011; 32(19): 2387-94.
  5. Raccah B.H. et al. major bleeding and hemorrhagic strokewith direct oral anticoagulants in patients with renal failure: Systematic Review and Meta-Analysis of Randomized Trials. Chest.2016; 149(6): 1516-24.
  6. Wheeler D.S., Giugliano R.P. and Rangaswami J. Anticoagulation- related
  7. Factor XA – Inhibition in RENal patients with Non-valvular Atrial fibrillation – Observational Registry (XARENO). Cited 2019; 18/02.
  8. Rivoraxabanvs Warfarin in AF patients with T2D and CKD (RE­ELECT). Cited 2019; 18/02.
  9. Bohm M. et al. Changes in renal Function in Patients with Atrial Fibrillation: An Analysis From the RE-LY Trial. J AM CollCardiol 2015; 65(23): 2481-93.
  10. Hijazi Z. et al. Efficacy and safety of Apixaban Compared with Warfarin in Patients with Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016; 1(14): 451-60.
  11. Fumagally S., Said S.A.M., Laroche C.,Gabbai D., Marchionni N, BorianiG., Maggioni A.P., Popescu M.I., Rasmussen R.H. et al.Age- Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). J Am CollCardiol EP. 2015; 1: 326-34.
  12. AbdullaevSh.S, IgamberdievaR.Sh. The use of new oral anticoagulants for atrial fibrillation in patients with chronic kidney disease. Therapeutic Bulletin of Uzbekistan 2018; 4: 151-155.

file

download